S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
This Stock Could Go Up 66% or More. (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
This Stock Could Go Up 66% or More. (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
This Stock Could Go Up 66% or More. (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
This Stock Could Go Up 66% or More. (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
This Stock Could Go Up 66% or More. (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
This Stock Could Go Up 66% or More. (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
This Stock Could Go Up 66% or More. (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
This Stock Could Go Up 66% or More. (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Earnings Date, Estimates & Call Transcripts

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$40.29
▼
$40.51
50-Day Range
$38.66
▼
$40.39
52-Week Range
$18.34
▼
$40.51
Volume
4.92 million shs
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.14
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Nov. 9Estimated
Actual EPS
(Aug. 7)
-$0.94 Missed By -$0.13
Consensus EPS
(Aug. 7)
-$0.81
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

KDNY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KDNY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Chinook Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20235($0.89)($0.75)($0.82)
Q2 20235($0.99)($0.68)($0.84)
Q3 20235($0.94)($0.68)($0.81)
Q4 20235($0.91)($0.67)($0.78)
FY 202320($3.73)($2.78)($3.25)
Q1 20242($0.80)($0.80)($0.80)
Q2 20242($0.87)($0.81)($0.84)
Q3 20242($0.88)($0.82)($0.85)
Q4 20242($0.92)($0.85)($0.89)
FY 20248($3.47)($3.28)($3.38)

KDNY Earnings Date and Information

Chinook Therapeutics last issued its earnings results on August 7th, 2023. The reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by $0.13. The company earned $1.01 million during the quarter, compared to analyst estimates of $0.47 million. Chinook Therapeutics has generated ($3.52) earnings per share over the last year (($3.52) diluted earnings per share). Earnings for Chinook Therapeutics are expected to decrease in the coming year, from ($3.30) to ($3.50) per share. Chinook Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off prior year's report dates.

Chinook Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/9/2023
Estimated)		------- 
8/7/2023Q2 2023($0.81)($0.94)($0.13)($0.94)$0.47 million$1.01 million
5/9/2023Q1 2023($0.82)($0.85)($0.03)($0.85)$0.14 million$1.83 million
2/27/2023Q4 2022($0.77)($0.90)($0.13)($0.90)$0.10 million$5.10 million
11/10/2022Q3 2022($0.62)($0.83)($0.21)($0.83)$0.35 million$2.50 million
8/8/2022Q2 2022($0.62)($0.61)+$0.01($0.61)$2.50 million$0.42 million
5/12/2022Q1 2022($0.68)($0.54)+$0.14($0.54)-$2.70 million    
3/17/2022Q4 2021($0.70)$0.14+$0.84$0.14-$51.24 million
11/7/2021Q3 2021($0.81)($0.69)+$0.12($0.67)--
8/12/2021Q2 2021($0.76)($0.68)+$0.08($0.39)$0.25 million$0.03 million
5/12/2021Q1 2021($0.61)($0.83)($0.22)($0.78)$0.25 million$0.35 million
4/6/2021Q4 2020($0.42)($1.24)($0.82)($1.14)-$0.83 million
11/5/2020Q3 2020($0.23)($0.90)($0.67)($0.90)$2.75 million$3.79 million












Chinook Therapeutics Earnings - Frequently Asked Questions

When is Chinook Therapeutics's earnings date?

Chinook Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off last year's report dates. Learn more on KDNY's earnings history.

Did Chinook Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Chinook Therapeutics (NASDAQ:KDNY) missed the analysts' consensus estimate of ($0.81) by $0.13 with a reported earnings per share (EPS) of ($0.94). Learn more on analysts' earnings estimate vs. KDNY's actual earnings.

How much revenue does Chinook Therapeutics generate each year?

Chinook Therapeutics (NASDAQ:KDNY) has a recorded annual revenue of $6.13 million.

How much profit does Chinook Therapeutics generate each year?

Chinook Therapeutics (NASDAQ:KDNY) has a recorded net income of -$187.87 million. KDNY has generated -$3.52 earnings per share over the last four quarters.

What is Chinook Therapeutics's EPS forecast for next year?

Chinook Therapeutics's earnings are expected to decrease from ($3.30) per share to ($3.50) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:KDNY) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -